CJC 1295 (without DAC)

CJC 1295 (without DAC) is a synthetic analog of the hypothalamic peptide GHRH/CJC-1295, originally developed for research applications in neuroendocrinology and neurobiology. This compound is designed to mimic the actions of growth hormone-releasing hormone (GHRH) and its analog, GHRP-6, while excluding the diacetylated amino terminus (DAC) modification. Research involving CJC 1295 has primarily explored its effects on pituitary gland function, neuroendocrine regulation, and potential applications in animal models.

Research Context

CJC 1295 was first introduced in the late 1980s as a potent analog of GHRH that binds to growth hormone-releasing hormone receptors (GHRHR) with high affinity. Early studies in rodents and primates demonstrated its ability to stimulate pituitary secretion of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without directly activating prolactin secretion, unlike some other GHRH analogs. The removal of the DAC modification alters its pharmacokinetic profile, making it a useful tool for examining receptor-specific signaling pathways and hormone release dynamics in controlled research settings.

Research Overview

In scientific research, CJC 1295 (without DAC) is utilized to study the mechanisms underlying neuroendocrine regulation, particularly focusing on the hypothalamic-pituitary axis. Researchers employ this compound to assess its effects on:

• Growth hormone secretion and IGF-1 production
• Neuroendocrine feedback loops in response to stress or hormonal challenges
• Behavioral and physiological adaptations in animal models

Its use in preclinical studies helps elucidate how peptide hormones interact with receptor systems at a molecular level, contributing to advancements in endocrinology and neurobiology.

Key Research Focus Areas

• Pituitary Function Studies: Investigation of GH and IGF-1 release in response to acute administration, including comparisons with DAC-modified analogs.
• Receptor Pharmacology: Examination of GHRHR binding affinity, signaling pathways, and differential activation of downstream effector molecules.
• Neuroendocrine Plasticity: Assessment of how CJC 1295 influences stress responses, circadian rhythms, and adaptive behavioral changes in animal models.
• Comparative Pharmacokinetics: Analysis of metabolic clearance and tissue distribution in comparison to other GHRH analogs.
• Preclinical Toxicology: Limited but relevant evaluations of potential off-target effects in controlled experimental settings.

Safety and Compliance Notice

CJC 1295 (without DAC) is a research chemical intended solely for use in accredited academic or industrial research facilities. This product is not approved for human or veterinary consumption, and its administration in any context outside of approved research protocols is prohibited. Researchers must adhere to regulatory guidelines, institutional policies, and ethical standards governing peptide use, including proper storage, handling, and disposal procedures. Failure to comply with these regulations may result in legal consequences or revocation of research permissions.